Dynavax Technologies Co. (NASDAQ:DVAX) Position Cut by Zurcher Kantonalbank Zurich Cantonalbank

Zurcher Kantonalbank Zurich Cantonalbank lowered its holdings in shares of Dynavax Technologies Co. (NASDAQ:DVAX) by 28.8% during the 4th quarter, Holdings Channel reports. The fund owned 122,207 shares of the biopharmaceutical company’s stock after selling 49,325 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Dynavax Technologies were worth $1,708,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors also recently added to or reduced their stakes in DVAX. Louisiana State Employees Retirement System bought a new stake in shares of Dynavax Technologies during the fourth quarter valued at about $905,000. Executive Wealth Management LLC bought a new stake in shares of Dynavax Technologies during the 4th quarter worth about $280,000. Allspring Global Investments Holdings LLC lifted its stake in shares of Dynavax Technologies by 185.6% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 118,074 shares of the biopharmaceutical company’s stock worth $1,651,000 after acquiring an additional 76,728 shares during the period. Wakefield Asset Management LLLP bought a new position in shares of Dynavax Technologies in the fourth quarter valued at approximately $828,000. Finally, Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Dynavax Technologies by 7.8% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 87,116 shares of the biopharmaceutical company’s stock valued at $1,218,000 after acquiring an additional 6,296 shares during the period. Institutional investors and hedge funds own 96.96% of the company’s stock.

Insider Buying and Selling

In other news, CAO Justin Burgess sold 20,526 shares of the company’s stock in a transaction on Friday, March 1st. The stock was sold at an average price of $12.78, for a total transaction of $262,322.28. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders own 2.98% of the company’s stock.

Dynavax Technologies Trading Down 2.9 %

Dynavax Technologies stock opened at $11.42 on Thursday. The firm has a market cap of $1.49 billion, a price-to-earnings ratio of -190.30 and a beta of 1.26. Dynavax Technologies Co. has a 1 year low of $10.06 and a 1 year high of $15.15. The firm’s 50 day moving average price is $12.28 and its two-hundred day moving average price is $13.23. The company has a debt-to-equity ratio of 0.41, a quick ratio of 12.96 and a current ratio of 13.81.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the company. StockNews.com downgraded Dynavax Technologies from a “buy” rating to a “hold” rating in a research report on Wednesday, April 17th. The Goldman Sachs Group began coverage on Dynavax Technologies in a report on Thursday, February 1st. They issued a “neutral” rating and a $20.00 price objective for the company. Finally, William Blair reaffirmed an “outperform” rating on shares of Dynavax Technologies in a report on Friday, February 23rd. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $25.00.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.